ECSP014079A - Derivados de sulfonamida - Google Patents

Derivados de sulfonamida

Info

Publication number
ECSP014079A
ECSP014079A EC2001004079A ECSP014079A ECSP014079A EC SP014079 A ECSP014079 A EC SP014079A EC 2001004079 A EC2001004079 A EC 2001004079A EC SP014079 A ECSP014079 A EC SP014079A EC SP014079 A ECSP014079 A EC SP014079A
Authority
EC
Ecuador
Prior art keywords
sulfonamide derivatives
hypofusion
psychiatric
graph
useful
Prior art date
Application number
EC2001004079A
Other languages
English (en)
Inventor
Paul Leslie Ornstein
Hamideh Zarrinmayeh
Dennis Michael Zimmerman
Andrew Hendley Fray
William David Miller
James Abraham Aikins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP014079A publication Critical patent/ECSP014079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula I (gráfico), o una sal farmacéuticamente aceptable del mismo, que es útil para el tratamiento de afecciones asociadas con la hipofusión como trastornos psiquiátricos y neurológicos.
EC2001004079A 2000-05-19 2001-05-18 Derivados de sulfonamida ECSP014079A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20582200P 2000-05-19 2000-05-19

Publications (1)

Publication Number Publication Date
ECSP014079A true ECSP014079A (es) 2002-02-25

Family

ID=22763775

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004079A ECSP014079A (es) 2000-05-19 2001-05-18 Derivados de sulfonamida

Country Status (25)

Country Link
US (2) US6720357B2 (es)
EP (1) EP1296944A1 (es)
JP (1) JP2003534315A (es)
KR (1) KR20030007643A (es)
CN (1) CN1429206A (es)
AR (1) AR028590A1 (es)
AU (1) AU2001262936A1 (es)
BR (1) BR0110871A (es)
CA (1) CA2409829A1 (es)
CZ (1) CZ20023796A3 (es)
DZ (1) DZ3344A1 (es)
EA (1) EA004868B1 (es)
EC (1) ECSP014079A (es)
HR (1) HRP20020917A2 (es)
HU (1) HUP0302291A3 (es)
IL (1) IL152154A0 (es)
MX (1) MXPA02010021A (es)
NO (1) NO20025533L (es)
NZ (1) NZ521620A (es)
PE (1) PE20011260A1 (es)
PL (1) PL358184A1 (es)
SK (1) SK16322002A3 (es)
SV (1) SV2002000458A (es)
WO (1) WO2001090056A1 (es)
ZA (1) ZA200208746B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
EP1438036A2 (en) * 2001-10-12 2004-07-21 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
EP1663113A4 (en) * 2003-09-18 2007-06-13 Merck & Co Inc SUBSTITUTED SULFONAMIDE
MY165918A (en) 2009-06-26 2018-05-18 Pfizer Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
KR101569842B1 (ko) 2009-09-30 2015-11-17 삼성전자 주식회사 텔레비전용 전원공급유닛 및 이를 포함하는 텔레비전
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
JP2016521755A (ja) 2013-06-13 2016-07-25 ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー 代謝障害を治療するための組成物および方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
PE20000942A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
PE20000943A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de sulfonamida
US6358982B1 (en) 1998-07-31 2002-03-19 Eli Lilly And Company Heterocyclyl sulphonamide derivatives
WO2000006537A1 (en) 1998-07-31 2000-02-10 Eli Lilly And Company N-substituted sulfonamide derivatives

Also Published As

Publication number Publication date
JP2003534315A (ja) 2003-11-18
EA004868B1 (ru) 2004-08-26
AR028590A1 (es) 2003-05-14
PE20011260A1 (es) 2001-12-11
MXPA02010021A (es) 2003-02-12
DZ3344A1 (fr) 2001-11-29
CN1429206A (zh) 2003-07-09
US20040143020A1 (en) 2004-07-22
US6803484B2 (en) 2004-10-12
HRP20020917A2 (en) 2004-02-29
NO20025533L (no) 2003-01-20
HUP0302291A3 (en) 2006-11-28
IL152154A0 (en) 2003-05-29
SV2002000458A (es) 2002-10-24
ZA200208746B (en) 2004-02-10
WO2001090056A1 (en) 2001-11-29
BR0110871A (pt) 2003-02-11
NZ521620A (en) 2004-08-27
NO20025533D0 (no) 2002-11-18
KR20030007643A (ko) 2003-01-23
CA2409829A1 (en) 2001-11-29
CZ20023796A3 (cs) 2003-04-16
PL358184A1 (en) 2004-08-09
EP1296944A1 (en) 2003-04-02
AU2001262936A1 (en) 2001-12-03
US20030233015A1 (en) 2003-12-18
HUP0302291A2 (hu) 2003-11-28
SK16322002A3 (sk) 2003-05-02
EA200201232A1 (ru) 2003-04-24
US6720357B2 (en) 2004-04-13

Similar Documents

Publication Publication Date Title
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
BR0311494A (pt) Novos indóis substituìdos
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
BR0312729A (pt) Novos derivados de indol-3-enxofre
MXPA04004370A (es) Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
DOP2006000170A (es) Nuevos derivados de espirocromanona
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
PA8591701A1 (es) Derivados de pirrolopirimidina
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
ATE440603T1 (de) 8-hydroxychinolinderivate
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
SV2002000462A (es) 5-cloro-3-(4-metansulfonilfenilo)-6'-metil-/2,3'/bipiridinilo en forma cristalina pura y proceso para la sintesis ref. b.12483/lg
DE60104697D1 (de) Sulfonamid-derivate
ECSP014079A (es) Derivados de sulfonamida
ES2189357T3 (es) Compustos isocromano y procedimiento para su produccion.
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
MX2024012967A (es) Derivados de piridina para el tratamiento de los trastornos psiquiatricos
SE0101082D0 (sv) Novel use
ECSP014078A (es) Derivados de sulfonamida